Normosang (Human Hemin)

Human Hemin delivers heme directly to the liver, where it provides negative feedback to the enzyme aminolevulinic acid synthase 1 (ALAS1). This feedback reduces the synthesis of delta‑aminolevulinic acid and other porphyrin precursors, lowering their toxic accumulation and interrupting an acute porphyria attack.

The dose of Normosang is individualized by the prescribing physician based on the severity of the porphyria attack, patient weight, and clinical response. Only a qualified healthcare professional should determine the appropriate dosing regimen.

Safety data for Human Hemin in pregnancy and lactation are limited. The drug should be used only if the potential benefit justifies any potential risk to the fetus or infant, and the decision must be made by the treating physician in consultation with the patient.

To request Normosang, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling if needed) and import documentation.

Normosang (Human Hemin) is the standard heme preparation for acute attacks, directly replacing deficient heme. Alternative therapies, such as glucose loading or other heme analogues, may be less potent or used only as adjuncts. Human Hemin offers rapid symptom control by targeting the underlying enzymatic pathway.

Normosang must be stored refrigerated at 2‑8 °C, protected from light, and should never be frozen or shaken. Keep the vial in its original packaging until use, and discard any solution that appears discolored or contains particles.

Normosang is given as an intravenous infusion. The solution is diluted according to the prescribing information and administered slowly under medical supervision, typically in a hospital or clinic setting equipped for intravenous therapy and monitoring of vital signs.

Serious risks include severe hypersensitivity reactions such as anaphylaxis, hemolysis (particularly in patients with G6PD deficiency), acute renal impairment, and significant hypotension. Prompt recognition and management of these events are essential, and patients should be monitored closely during and after infusion.

Normosang is contraindicated in individuals with known hypersensitivity to Human Hemin or any excipients in the formulation. Caution is also advised for patients with severe renal or hepatic impairment, G6PD deficiency, or those receiving interacting medications listed under major interactions.